<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910907</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300003178</org_study_id>
    <nct_id>NCT03910907</nct_id>
  </id_info>
  <brief_title>Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis</brief_title>
  <official_title>Comparison of Current Standard of Care Versus the Australian Guidelines for Management of Mycoplasma Genitalium Infections Among Men Being Treated for Non-gonococcal Urethritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine the difference in clearance of Mycoplasma
      genitalium (MG) when using the Australian management protocol versus the current Centers of
      Disease Control (CDC) treatment guidelines for US standard of care (SOC), to determine the
      proportion of men from the Deep South, with NGU attributable to MG, and to determine the
      proportion of MG cases that harbor the macrolide-resistance associated with mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycoplasma genitalium (MG) has been associated with non-gonococcal urethritis (NGU) in many
      populations and the prevalence of MG strains with macrolide-resistance associated gene
      mutations is increasing . While no MG diagnostic assays have FDA clearance in the United
      States (US), treatment for NGU is primarily focused on managing potential infection with
      Chlamydia trachomatis (CT) using single dose 1 gm Azithromycin (a macrolide class of drug).
      Without testing for MG that might alter NGU treatment strategies, the current paradigm may be
      contributing to selective pressure resulting in increased macrolide resistance in MG. In
      Australia, awareness of the prevalence of MG and macrolide resistance-associated mutations
      has been facilitated by an approved diagnostic test manufactured by SpeeDx. Ltd. As a result
      of the epidemiologic information generated by this diagnostic tool [MG ResistancePlus (MRP)
      Assay], the Australian Sexual Health Alliance, who publish the Australian Sexually
      Transmitted Infection (STI) Management Guidelines for Use in Primary Care, have revised the
      management of men with NGU and MG infection. The new management guidelines include initial
      treatment of NGU with doxycycline, and concomitant testing for MG and macrolide resistance,
      with subsequent treatment for MG infected patients according to resistance results. We
      propose using the MRP assay in a population of men with NGU to determine the clinical impact
      of the Australian treatment strategy compared to the current standard of care for NGU on
      clearance of MG infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with Molecular Clearance</measure>
    <time_frame>90 days</time_frame>
    <description>DNA negative for mycoplasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Participants with Macrolide-Resistant Mycoplasma</measure>
    <time_frame>90 days</time_frame>
    <description>DNA positive for macrolide-resistant mycoplasma</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Mycoplasma Genitalium Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <description>Men treated for mycoplasma according to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus</arm_group_label>
    <description>Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparison of two standard of care regimens</intervention_name>
    <description>Treatment according to results of laboratory detection of resistance markers</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Standard of care plus</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual urine samples will be retained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men with non-gonoccocal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting with symptoms of urethritis (dysuria and/or urethral discharge)

        Exclusion Criteria:

          -  Non-English speaking
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Van Der Pol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles A Rivers, PhD</last_name>
    <phone>205-996-4023</phone>
    <email>rivers@uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Van Der Pol, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Barbara Van Der Pol</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>mycoplasma genitalium</keyword>
  <keyword>urethritis</keyword>
  <keyword>NGU</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoplasma Infections</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Urethritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

